KTTA (Pasithea) גידול ברווח למניה בשנה הנוכחית

Neurodrug production capacities are utilized according to clinical plans, and equipment is undergoing sterilization. Molecule synthesis and testing have been fully outsourced to external contractors. EPS YoY volatility demonstrates profit dynamics, where the value of 73.50 expresses the metric level. Pasithea Therapeutics (KTTA) is developing targeted depression therapy in US and UK centers, leveraging active research.
פילוחי מדדים מקיפים ואנליטיקה עבור pasitheaclinics.com (KTTA)

For Pasithea Therapeutics (KTTA), which balances clinical trials with the operational business of ketamine centers, this indicator serves as a measure of the effectiveness of this diversification. The metric calculates the percentage deviation of current earnings per share from the same value last year, isolating the fundamental trend from market volatility. By analyzing the annual evolution of earnings per share, an investor can assess how successfully Pasithea Therapeutics converts scientific developments into real financial growth.